Igor Kobzev, the Governor of the Irkutsk Region, and Vladimir Yakushev, the First Deputy Chairman of the Federation Council, paid a visit to the Pharmasyntez Group's Irkutsk plant on April 17, 2025. Familiarization with the manufacturing of the newest medications and a discussion of the company's main tasks with the management were part of the working visit. Involving competent specialists is one of the top priorities since they will be essential to the plant's continued development.
By late 2025, Pharmasyntez intends to begin producing bronchodilators bronchodilator medications in Irkutsk to treat bronchial asthma and chronic obstructive pulmonary disease. This significant move will boost the local economy by adding 90 new jobs and diversifying the company's product portfolio.
“Pharmasyntez makes significant contributions to the Priangarye region's development as a reliable employer and taxpayer” underlined Igor Kobzev, the Irkutsk Region Governor. “The enterprise shows dynamic growth and needs skilled personnel. We observe that the business is adapting by drawing in and educating young specialists”.
“Our people's program has special control over the development of the pharmaceutical industry”, said Vladimir Yakushev, First Deputy Chairman of the Federation Council. “After speaking with Mikhail Mishustin about the progress of import substitution in this area, we gave this issue particular attention during the Government's report. We witnessed firsthand today how the businesses that have been actively occupying this niche are growing. Their drug portfolio is expanding, and a youthful team has been assembled to look ahead and plan investment projects. We can confidently state that we will undoubtedly obtain the medications that our residents require and desire at this location today. And with the aid of these businesses and their human resources, we can get past the difficult external circumstances that are currently affecting our nation”.
The delegation visited department No. 5, which produces sterile and solid sterile dosage forms. The department commissioned a new high-capacity ampoule-syringe production line this year. Twelve products from eight therapeutic groups make up the assortment. These products are meant to prevent and treat common and socially significant diseases, support and perform surgical procedures, and ensure that patients recover as best they can.
“We are constantly focused on development while operating within the parameters of our long-term strategy” stated Yevgeny Orachevsky, CEO of Pharmasyntez JSC. “This is an ongoing process, and our top goal is to build more production capacity so that we can manufacture high-quality, affordable medications. When it comes to registering new products in Russia, Pharmasyntez is among the top companies.